A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.
Malaria is a major infectious disease caused by a unicellular parasite. The parasite has a complicated life cycle with stages in humans and mosquitoes (see "About Malaria" below). The first stage in humans takes place in the liver, then infection of the blood follows with clinical symptoms and complications. Since the liver phase does not cause any symptoms, the purpose of the vaccine is to stop the parasite for safety in the liver. Parasites in the liver can already trigger a protective immune response.
Using a rodent malaria parasiteThe vaccine in this study, called PbVac, belongs to a new class of whole-organism vaccines. It makes use of intact parasites, in this case a malaria parasite that is harmless to humans and can only infect mice (Plasmodium berghei). With genetic modification, an important protein of the human malaria parasite was added in order to evoke a protective immune response.
An international consortium, in which Professor of Medical Parasitology Robert Sauerwein, theme Infectious diseases and global health, collaborated with Miguel Prudêncio of the Portuguese Instituto de Medicina Molecular and Perry van Genderen of Erasmus MC, has now completed a clinical trial. Prudêncio: “Following the pre-clinical validation of PbVac’s immunogenicity and safety for human use, we have carried out, with funding and advice from PATH’s Malaria Vaccine Initiative, a first-in-humans Phase 1/2a clinical trial, involving a total of 24 healthy volunteers, to ascertain PbVac’s safety and protective efficacy in the clinic.” Although none of the 24 subjects were fully protected, the infection with malaria parasites in the liver decreased by 95%.
Proof of principleThe results are a promising step towards an effective vaccine. Van Genderen: “The use of this smart transgenic Pberghei sporozoite immunization platform has substantially widened the potential for development of new vaccines in humans.”
Sauerwein concludes: “An effective vaccine is an essential part of a broad strategy in the fight against malaria. This approach shows that it works in principle, but that the composition of the vaccine or dose need to be adjusted.”
About malariaMalaria is one of the major infectious diseases of our time with around 216 million cases and 400,000 deaths annually. In recent years there has been an increase in the number of infections, especially in Sub-Saharan Africa and South America.
The most deadly form of malaria for humans is caused by the single-celled parasite Plasmodium falciparum, which is transmitted by mosquitoes to humans and vice versa. Once in humans, the parasite develops from an asexual cell into mature male and female germ cells in five stages. These cells can then be sucked up again by mosquitoes, after which fertilization of the parasites takes place in the mosquito stomach. The offspring can return to humans after another mosquito bite. Preventing the spread of malaria is considered to be one of the greatest challenges in the fight against the disease.
Related news items
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more
ERC Proof of Concept grant received by Ronald van Rij30 July 2020
Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.read more
Hypatia fellowship Call is open30 July 2020
The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.read more
Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation.29 July 2020
These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.read more
Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process28 July 2020
''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.read more